Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions.

Frontiers in pharmacology

Uzun AU, Mannhardt I, Breckwoldt K, Horváth A, Johannsen SS, Hansen A, Eschenhagen T, Christ T.
PMID: 27672365
Front Pharmacol. 2016 Sep 12;7:300. doi: 10.3389/fphar.2016.00300. eCollection 2016.

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) provide a unique opportunity to study human heart physiology and pharmacology and repair injured hearts. The suitability of hiPSC-CM critically depends on how closely they share physiological properties of human adult cardiomyocytes...

Cite
Uzun AU, Mannhardt I, Breckwoldt K, et al. Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Front Pharmacol. 2016;7:300doi: 10.3389/fphar.2016.00300.
Uzun, A. U., Mannhardt, I., Breckwoldt, K., Horváth, A., Johannsen, S. S., Hansen, A., Eschenhagen, T., & Christ, T. (2016). Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Frontiers in pharmacology, 7300. https://doi.org/10.3389/fphar.2016.00300
Uzun, Ahmet U, et al. "Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions." Frontiers in pharmacology vol. 7 (2016): 300. doi: https://doi.org/10.3389/fphar.2016.00300
Uzun AU, Mannhardt I, Breckwoldt K, Horváth A, Johannsen SS, Hansen A, Eschenhagen T, Christ T. Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Front Pharmacol. 2016 Sep 12;7:300. doi: 10.3389/fphar.2016.00300. eCollection 2016. PMID: 27672365; PMCID: PMC5018497.
Copy Download .nbib Format: NLM
Thymosin .

Stem cells international

Ziegler T, Hinkel R, Stöhr A, Eschenhagen T, Laugwitz KL, le Noble F, David R, Hansen A, Kupatt C.
PMID: 28191018
Stem Cells Int. 2017;2017:6848271. doi: 10.1155/2017/6848271. Epub 2017 Jan 16.

Induced pluripotent stem cells (iPSC) constitute a powerful tool to study cardiac physiology and represents a promising treatment strategy to tackle cardiac disease. However, iPSCs remain relatively immature after differentiation. Additionally, engineered heart tissue (EHT) has been investigated as...

Cite
Ziegler T, Hinkel R, Stöhr A, et al. Thymosin . Stem Cells Int. 2017;2017:6848271doi: 10.1155/2017/6848271.
Ziegler, T., Hinkel, R., Stöhr, A., Eschenhagen, T., Laugwitz, K. L., le Noble, F., David, R., Hansen, A., & Kupatt, C. (2017). Thymosin . Stem cells international, 20176848271. https://doi.org/10.1155/2017/6848271
Ziegler, Tilman, et al. "Thymosin ." Stem cells international vol. 2017 (2017): 6848271. doi: https://doi.org/10.1155/2017/6848271
Ziegler T, Hinkel R, Stöhr A, Eschenhagen T, Laugwitz KL, le Noble F, David R, Hansen A, Kupatt C. Thymosin . Stem Cells Int. 2017;2017:6848271. doi: 10.1155/2017/6848271. Epub 2017 Jan 16. PMID: 28191018; PMCID: PMC5278226.
Copy Download .nbib Format: NLM
Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue.

PloS one

Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, Stenzig J, Force T, Eschenhagen T, Hansen A.
PMID: 30481219
PLoS One. 2018 Nov 27;13(11):e0208342. doi: 10.1371/journal.pone.0208342. eCollection 2018.

[This corrects the article DOI: 10.1371/journal.pone.0145937.].

Cite
Jacob F, Yonis AY, Cuello F, et al. Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS One. 2018;13(11):e0208342doi: 10.1371/journal.pone.0208342.
Jacob, F., Yonis, A. Y., Cuello, F., Luther, P., Schulze, T., Eder, A., Streichert, T., Mannhardt, I., Hirt, M. N., Schaaf, S., Stenzig, J., Force, T., Eschenhagen, T., & Hansen, A. (2018). Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PloS one, 13(11), e0208342. https://doi.org/10.1371/journal.pone.0208342
Jacob, Fabian, et al. "Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue." PloS one vol. 13,11 (2018): e0208342. doi: https://doi.org/10.1371/journal.pone.0208342
Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, Streichert T, Mannhardt I, Hirt MN, Schaaf S, Stenzig J, Force T, Eschenhagen T, Hansen A. Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS One. 2018 Nov 27;13(11):e0208342. doi: 10.1371/journal.pone.0208342. eCollection 2018. PMID: 30481219; PMCID: PMC6258548.
Copy Download .nbib Format: NLM
Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner.

Circulation

Querdel E, Reinsch M, Castro L, Köse D, Bähr A, Reich S, Geertz B, Ulmer B, Schulze M, Lemoine MD, Krause T, Lemme M, Sani J, Shibamiya A, Stüdemann T, Köhne M, Bibra CV, Hornaschewitz N, Pecha S, Nejahsie Y, Mannhardt I, Christ T, Reichenspurner H, Hansen A, Klymiuk N, Krane M, Kupatt C, Eschenhagen T, Weinberger F.
PMID: 33648345
Circulation. 2021 May 18;143(20):1991-2006. doi: 10.1161/CIRCULATIONAHA.120.047904. Epub 2021 Mar 02.

BACKGROUND: Human engineered heart tissue (EHT) transplantation represents a potential regenerative strategy for patients with heart failure and has been successful in preclinical models. Clinical application requires upscaling, adaptation to good manufacturing practices, and determination of the effective dose.METHODS:...

Cite
Querdel E, Reinsch M, Castro L, et al. Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. Circulation. 2021;143(20):1991-2006doi: 10.1161/CIRCULATIONAHA.120.047904.
Querdel, E., Reinsch, M., Castro, L., Köse, D., Bähr, A., Reich, S., Geertz, B., Ulmer, B., Schulze, M., Lemoine, M. D., Krause, T., Lemme, M., Sani, J., Shibamiya, A., Stüdemann, T., Köhne, M., Bibra, C. V., Hornaschewitz, N., Pecha, S., Nejahsie, Y., Mannhardt, I., Christ, T., Reichenspurner, H., Hansen, A., Klymiuk, N., Krane, M., Kupatt, C., Eschenhagen, T., & Weinberger, F. (2021). Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. Circulation, 143(20), 1991-2006. https://doi.org/10.1161/CIRCULATIONAHA.120.047904
Querdel, Eva, et al. "Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner." Circulation vol. 143,20 (2021): 1991-2006. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047904
Querdel E, Reinsch M, Castro L, Köse D, Bähr A, Reich S, Geertz B, Ulmer B, Schulze M, Lemoine MD, Krause T, Lemme M, Sani J, Shibamiya A, Stüdemann T, Köhne M, Bibra CV, Hornaschewitz N, Pecha S, Nejahsie Y, Mannhardt I, Christ T, Reichenspurner H, Hansen A, Klymiuk N, Krane M, Kupatt C, Eschenhagen T, Weinberger F. Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. Circulation. 2021 May 18;143(20):1991-2006. doi: 10.1161/CIRCULATIONAHA.120.047904. Epub 2021 Mar 02. PMID: 33648345; PMCID: PMC8126500.
Copy Download .nbib Format: NLM
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC).

European journal of heart failure

de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, Eschenhagen T, Filippatos G, Gepstein L, Hulot JS, Knöll R, Kupatt C, Linke WA, Seidman CE, Tocchetti CG, van der Velden J, Walsh R, Seferovic PM, Thum T.
PMID: 34969177
Eur J Heart Fail. 2021 Dec 30; doi: 10.1002/ejhf.2414. Epub 2021 Dec 30.

Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton, or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology-specific...

Cite
de Boer RA, Heymans S, Backs J, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2414.
de Boer, R. A., Heymans, S., Backs, J., Carrier, L., Coats, A. J. S., Dimmeler, S., Eschenhagen, T., Filippatos, G., Gepstein, L., Hulot, J. S., Knöll, R., Kupatt, C., Linke, W. A., Seidman, C. E., Tocchetti, C. G., van der Velden, J., Walsh, R., Seferovic, P. M., & Thum, T. (2021). Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European journal of heart failure, . https://doi.org/10.1002/ejhf.2414
de Boer, Rudolf A, et al. "Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2414
de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, Eschenhagen T, Filippatos G, Gepstein L, Hulot JS, Knöll R, Kupatt C, Linke WA, Seidman CE, Tocchetti CG, van der Velden J, Walsh R, Seferovic PM, Thum T. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail. 2021 Dec 30; doi: 10.1002/ejhf.2414. Epub 2021 Dec 30. PMID: 34969177.
Copy Download .nbib Format: NLM
Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

International journal of molecular sciences

Badone B, Ronchi C, Lodola F, Knaust AE, Hansen A, Eschenhagen T, Zaza A.
PMID: 34948294
Int J Mol Sci. 2021 Dec 16;22(24). doi: 10.3390/ijms222413500.

Phospholamban (PLN) is the natural inhibitor of the sarco/endoplasmic reticulum CaAIM: To test in cardiomyocytes (hiPSC-CMs) derived from a PLN p.Arg14del carrier whether (1) CaMETHODS: CaRESULTS: WT and MUT differed for the following properties: (1) CaT time to peak...

Cite
Badone B, Ronchi C, Lodola F, et al. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413500.
Badone, B., Ronchi, C., Lodola, F., Knaust, A. E., Hansen, A., Eschenhagen, T., & Zaza, A. (2021). Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413500
Badone, Beatrice, et al. "Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413500
Badone B, Ronchi C, Lodola F, Knaust AE, Hansen A, Eschenhagen T, Zaza A. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int J Mol Sci. 2021 Dec 16;22(24). doi: 10.3390/ijms222413500. PMID: 34948294; PMCID: PMC8709382.
Copy Download .nbib Format: NLM
Regulation of basal and norepinephrine-induced cAMP and I.

Cellular signalling

Iqbal Z, Ismaili D, Dolce B, Petersen J, Reichenspurner H, Hansen A, Kirchhof P, Eschenhagen T, Nikolaev VO, Molina CE, Christ T.
PMID: 33677066
Cell Signal. 2021 Jun;82:109970. doi: 10.1016/j.cellsig.2021.109970. Epub 2021 Mar 05.

BACKGROUND: There is ongoing interest in generating cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) to study human cardiac physiology and pathophysiology. Recently we found that norepinephrine-stimulated calcium currents (IMETHODS: Adult human atrial cardiomyocytes were isolated from tissue...

Cite
Iqbal Z, Ismaili D, Dolce B, et al. Regulation of basal and norepinephrine-induced cAMP and I. Cell Signal. 2021;82:109970doi: 10.1016/j.cellsig.2021.109970.
Iqbal, Z., Ismaili, D., Dolce, B., Petersen, J., Reichenspurner, H., Hansen, A., Kirchhof, P., Eschenhagen, T., Nikolaev, V. O., Molina, C. E., & Christ, T. (2021). Regulation of basal and norepinephrine-induced cAMP and I. Cellular signalling, 82109970. https://doi.org/10.1016/j.cellsig.2021.109970
Iqbal, Zafar, et al. "Regulation of basal and norepinephrine-induced cAMP and I." Cellular signalling vol. 82 (2021): 109970. doi: https://doi.org/10.1016/j.cellsig.2021.109970
Iqbal Z, Ismaili D, Dolce B, Petersen J, Reichenspurner H, Hansen A, Kirchhof P, Eschenhagen T, Nikolaev VO, Molina CE, Christ T. Regulation of basal and norepinephrine-induced cAMP and I. Cell Signal. 2021 Jun;82:109970. doi: 10.1016/j.cellsig.2021.109970. Epub 2021 Mar 05. PMID: 33677066.
Copy Download .nbib Format: NLM
A magnetics-based approach for fine-tuning afterload in engineered heart tissues.

ACS biomaterials science & engineering

Rodriguez ML, Werner TR, Becker B, Eschenhagen T, Hirt MN.
PMID: 31637285
ACS Biomater Sci Eng. 2019 Jul 08;5(7):3663-3675. doi: 10.1021/acsbiomaterials.8b01568. Epub 2019 Jun 11.

Afterload plays important roles during heart development and disease progression, however, studying these effects in a laboratory setting is challenging. Current techniques lack the ability to precisely and reversibly alter afterload over time. Here, we describe a magnetics-based approach...

Cite
Rodriguez ML, Werner TR, Becker B, et al. A magnetics-based approach for fine-tuning afterload in engineered heart tissues. ACS Biomater Sci Eng. 2019;5(7):3663-3675doi: 10.1021/acsbiomaterials.8b01568.
Rodriguez, M. L., Werner, T. R., Becker, B., Eschenhagen, T., & Hirt, M. N. (2019). A magnetics-based approach for fine-tuning afterload in engineered heart tissues. ACS biomaterials science & engineering, 5(7), 3663-3675. https://doi.org/10.1021/acsbiomaterials.8b01568
Rodriguez, Marita L, et al. "A magnetics-based approach for fine-tuning afterload in engineered heart tissues." ACS biomaterials science & engineering vol. 5,7 (2019): 3663-3675. doi: https://doi.org/10.1021/acsbiomaterials.8b01568
Rodriguez ML, Werner TR, Becker B, Eschenhagen T, Hirt MN. A magnetics-based approach for fine-tuning afterload in engineered heart tissues. ACS Biomater Sci Eng. 2019 Jul 08;5(7):3663-3675. doi: 10.1021/acsbiomaterials.8b01568. Epub 2019 Jun 11. PMID: 31637285; PMCID: PMC6803165.
Copy Download .nbib Format: NLM
Akrinor.

Frontiers in pharmacology

Kloth B, Pecha S, Moritz E, Schneeberger Y, Söhren KD, Schwedhelm E, Reichenspurner H, Eschenhagen T, Böger RH, Christ T, Stehr SN.
PMID: 28588484
Front Pharmacol. 2017 May 23;8:272. doi: 10.3389/fphar.2017.00272. eCollection 2017.

No abstract available.

Cite
Kloth B, Pecha S, Moritz E, et al. Akrinor. Front Pharmacol. 2017;8:272doi: 10.3389/fphar.2017.00272.
Kloth, B., Pecha, S., Moritz, E., Schneeberger, Y., Söhren, K. D., Schwedhelm, E., Reichenspurner, H., Eschenhagen, T., Böger, R. H., Christ, T., & Stehr, S. N. (2017). Akrinor. Frontiers in pharmacology, 8272. https://doi.org/10.3389/fphar.2017.00272
Kloth, Benjamin, et al. "Akrinor." Frontiers in pharmacology vol. 8 (2017): 272. doi: https://doi.org/10.3389/fphar.2017.00272
Kloth B, Pecha S, Moritz E, Schneeberger Y, Söhren KD, Schwedhelm E, Reichenspurner H, Eschenhagen T, Böger RH, Christ T, Stehr SN. Akrinor. Front Pharmacol. 2017 May 23;8:272. doi: 10.3389/fphar.2017.00272. eCollection 2017. PMID: 28588484; PMCID: PMC5441130.
Copy Download .nbib Format: NLM
Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles.

JACC. Basic to translational science

Eschenhagen T.
PMID: 30062213
JACC Basic Transl Sci. 2018 May 30;3(2):277-279. doi: 10.1016/j.jacbts.2018.01.011. eCollection 2018 Apr.

No abstract available.

Cite
Eschenhagen T. Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles. JACC Basic Transl Sci. 2018;3(2):277-279doi: 10.1016/j.jacbts.2018.01.011.
Eschenhagen, T. (2018). Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles. JACC. Basic to translational science, 3(2), 277-279. https://doi.org/10.1016/j.jacbts.2018.01.011
Eschenhagen, Thomas. "Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles." JACC. Basic to translational science vol. 3,2 (2018): 277-279. doi: https://doi.org/10.1016/j.jacbts.2018.01.011
Eschenhagen T. Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles. JACC Basic Transl Sci. 2018 May 30;3(2):277-279. doi: 10.1016/j.jacbts.2018.01.011. eCollection 2018 Apr. PMID: 30062213; PMCID: PMC6060270.
Copy Download .nbib Format: NLM
[25 years of progress in pharmacology: many innovations--are you up to date?].

MMW Fortschritte der Medizin

Eeschenhagen T, Rau T.
PMID: 19125519
MMW Fortschr Med. 2008 Nov 27;150(48):130, 132, 134.

No abstract available.

Cite
Eeschenhagen T, Rau T. Pharmakologie. Zahlreiche Innovationen: Sind Sie up to date? [25 years of progress in pharmacology: many innovations--are you up to date?]. MMW Fortschr Med. 2008;150(48):130, 132, 134
Eeschenhagen, T., & Rau, T. (2008). Pharmakologie. Zahlreiche Innovationen: Sind Sie up to date? [25 years of progress in pharmacology: many innovations--are you up to date?]. MMW Fortschritte der Medizin, 150(48), 130, 132, 134.
Eeschenhagen, Thomas, and Rau, Thomas. "Pharmakologie. Zahlreiche Innovationen: Sind Sie up to date?" [25 years of progress in pharmacology: many innovations--are you up to date?]. MMW Fortschritte der Medizin vol. 150,48 (2008): 130, 132, 134.
Eeschenhagen T, Rau T. Pharmakologie. Zahlreiche Innovationen: Sind Sie up to date? [25 years of progress in pharmacology: many innovations--are you up to date?]. MMW Fortschr Med. 2008 Nov 27;150(48):130, 132, 134. German. PMID: 19125519.
Copy Download .nbib Format: NLM
Genetic diversification of persistent .

Virulence

Lewin A, Kamal E, Semmler T, Winter K, Kaiser S, Schäfer H, Mao L, Eschenhagen P, Grehn C, Bender J, Schwarz C.
PMID: 34546836
Virulence. 2021 Dec;12(1):2415-2429. doi: 10.1080/21505594.2021.1959808.

No abstract available.

Cite
Lewin A, Kamal E, Semmler T, et al. Genetic diversification of persistent . Virulence. 2021;12(1):2415-2429doi: 10.1080/21505594.2021.1959808.
Lewin, A., Kamal, E., Semmler, T., Winter, K., Kaiser, S., Schäfer, H., Mao, L., Eschenhagen, P., Grehn, C., Bender, J., & Schwarz, C. (2021). Genetic diversification of persistent . Virulence, 12(1), 2415-2429. https://doi.org/10.1080/21505594.2021.1959808
Lewin, Astrid, et al. "Genetic diversification of persistent ." Virulence vol. 12,1 (2021): 2415-2429. doi: https://doi.org/10.1080/21505594.2021.1959808
Lewin A, Kamal E, Semmler T, Winter K, Kaiser S, Schäfer H, Mao L, Eschenhagen P, Grehn C, Bender J, Schwarz C. Genetic diversification of persistent . Virulence. 2021 Dec;12(1):2415-2429. doi: 10.1080/21505594.2021.1959808. PMID: 34546836; PMCID: PMC8526041.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries